1186 related articles for article (PubMed ID: 16290254)
1. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Patri AK; Kukowska-Latallo JF; Baker JR
Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
[TBL] [Abstract][Full Text] [Related]
2. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
3. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality.
Majoros IJ; Myc A; Thomas T; Mehta CB; Baker JR
Biomacromolecules; 2006 Feb; 7(2):572-9. PubMed ID: 16471932
[TBL] [Abstract][Full Text] [Related]
4. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of dendrimers and drug-dendrimer conjugates for drug delivery.
Najlah M; D'Emanuele A
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):756-67. PubMed ID: 17987527
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of 2-methoxyestradiol within multifunctional poly(amidoamine) dendrimers for targeted cancer therapy.
Wang Y; Guo R; Cao X; Shen M; Shi X
Biomaterials; 2011 Apr; 32(12):3322-9. PubMed ID: 21315444
[TBL] [Abstract][Full Text] [Related]
7. Targeting and inhibition of cell growth by an engineered dendritic nanodevice.
Thomas TP; Majoros IJ; Kotlyar A; Kukowska-Latallo JF; Bielinska A; Myc A; Baker JR
J Med Chem; 2005 Jun; 48(11):3729-35. PubMed ID: 15916424
[TBL] [Abstract][Full Text] [Related]
8. Dendrimer toxicity: Let's meet the challenge.
Jain K; Kesharwani P; Gupta U; Jain NK
Int J Pharm; 2010 Jul; 394(1-2):122-42. PubMed ID: 20433913
[TBL] [Abstract][Full Text] [Related]
9. Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload.
Kolhe P; Khandare J; Pillai O; Kannan S; Lieh-Lai M; Kannan RM
Biomaterials; 2006 Feb; 27(4):660-9. PubMed ID: 16054211
[TBL] [Abstract][Full Text] [Related]
10. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
Singh P; Gupta U; Asthana A; Jain NK
Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215
[TBL] [Abstract][Full Text] [Related]
11. Host-guest chemistry of dendrimer-drug complexes. 3. Competitive binding of multiple drugs by a single dendrimer for combination therapy.
Zhao L; Cheng Y; Hu J; Wu Q; Xu T
J Phys Chem B; 2009 Oct; 113(43):14172-9. PubMed ID: 19788172
[TBL] [Abstract][Full Text] [Related]
12. HPLC analysis of PAMAM dendrimer based multifunctional devices.
Islam MT; Majoros IJ; Baker JR
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Aug; 822(1-2):21-6. PubMed ID: 15950555
[TBL] [Abstract][Full Text] [Related]
13. Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications.
Yellepeddi VK; Kumar A; Palakurthi S
Expert Opin Drug Deliv; 2009 Aug; 6(8):835-50. PubMed ID: 19637972
[TBL] [Abstract][Full Text] [Related]
14. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers.
Kurtoglu YE; Mishra MK; Kannan S; Kannan RM
Int J Pharm; 2010 Jan; 384(1-2):189-94. PubMed ID: 19825406
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug.
Ma M; Cheng Y; Xu Z; Xu P; Qu H; Fang Y; Xu T; Wen L
Eur J Med Chem; 2007 Jan; 42(1):93-8. PubMed ID: 17095123
[TBL] [Abstract][Full Text] [Related]
16. Dendrimers as versatile platform in drug delivery applications.
Svenson S
Eur J Pharm Biopharm; 2009 Mar; 71(3):445-62. PubMed ID: 18976707
[TBL] [Abstract][Full Text] [Related]
17. In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core.
Zhang XQ; Wang XL; Huang SW; Zhuo RX; Liu ZL; Mao HQ; Leong KW
Biomacromolecules; 2005; 6(1):341-50. PubMed ID: 15638538
[TBL] [Abstract][Full Text] [Related]
18. Design considerations for PAMAM dendrimer therapeutics.
Goonewardena SN; Kratz JD; Zong H; Desai AM; Tang S; Emery S; Baker JR; Huang B
Bioorg Med Chem Lett; 2013 May; 23(10):2872-5. PubMed ID: 23583511
[TBL] [Abstract][Full Text] [Related]
19. Solubility of nicotinic acid in polyamidoamine dendrimer solutions.
Yiyun C; Tongwen X
Eur J Med Chem; 2005 Dec; 40(12):1384-9. PubMed ID: 16226352
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins.
Devarakonda B; Hill RA; Liebenberg W; Brits M; de Villiers MM
Int J Pharm; 2005 Nov; 304(1-2):193-209. PubMed ID: 16198076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
